10-Q
Quarterly Report
Translational Development Acquisition Corp. TDAC TDACU TDACW
0001104659-26-061556
- Filed
- May 15, 2026 12:00 AM ET
- Period of report
- —
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Operating Cash Flow | Q1 2026 · Mar 31, 2026 | −$305.16K |
| Operating Cash Flow | Q1 2026 · Mar 31, 2025 | −$231.57K |
| Cash And Equivalents | Q1 2026 · Mar 31, 2026 | $24.63K |
| Cash And Equivalents | Q1 2026 · Dec 31, 2025 | $29.79K |
| Stockholders Equity | Q1 2026 · Mar 31, 2026 | −$6.82M |
| Stockholders Equity | Q1 2026 · Dec 31, 2025 | −$6.54M |
| Stockholders Equity | Q1 2026 · Mar 31, 2025 | −$5.94M |
| Stockholders Equity | Q1 2026 · Dec 31, 2024 | −$5.6M |
| Current Liabilities | Q1 2026 · Mar 31, 2026 | $861.09K |
| Current Liabilities | Q1 2026 · Dec 31, 2025 | $544.07K |
| Total Liabilities | Q1 2026 · Mar 31, 2026 | $6.9M |
| Total Liabilities | Q1 2026 · Dec 31, 2025 | $6.58M |
| Current Assets | Q1 2026 · Mar 31, 2026 | $75.32K |
| Current Assets | Q1 2026 · Dec 31, 2025 | $39.47K |
| Total Assets | Q1 2026 · Mar 31, 2026 | $183.35M |
| Total Assets | Q1 2026 · Dec 31, 2025 | $181.7M |
| Sga Expense | Q1 2026 · Mar 31, 2026 | $281.16K |
| Sga Expense | Q1 2026 · Mar 31, 2025 | $347.41K |
| Net Income | Q1 2026 · Mar 31, 2026 | $1.33M |
| Net Income | Q1 2026 · Mar 31, 2025 | $1.48M |
| Operating Income | Q1 2026 · Mar 31, 2026 | −$281.16K |
| Operating Income | Q1 2026 · Mar 31, 2025 | −$347.41K |